Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

• Príomhchruthaitheoirí: Alexander Egeberg (Údar), Denis Jullien (Údar), Kristian Gaarn Du Jardin (Údar), Diamant Thaçi (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Background Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure. Objectives To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and t...